Lupin gets USFDA nod for Asthma drug

PTI New Delhi | Updated on November 13, 2018 Published on November 13, 2018

Drug major Lupin on Tuesday said it has received approval from the US health regulator to market Budesonide Inhalation Suspension single-dose ampoules, used for treating Asthma.

The product approved by the United States Food and Drug Administration (USFDA) is a generic version of AstraZeneca Pharmaceuticals LP’s Pulmicort Respules Inhalation Suspension, 0.5 mg/2 mL, Lupin said in a regulatory filing.

Quoting IQVIA MAT September data, Lupin said, the said Asthma drug had annual sales of around $ 474.5 million in the US.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on November 13, 2018
This article is closed for comments.
Please Email the Editor